UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 216

Sortiert nach

Effect of Tipranavir/Ritonavir Combination on the Pharmacokinetics of Tadalafil in Healthy Volunteers

Journal of clinical pharmacology, 2011-07, Vol.51 (7), p.1071-1078

2011

Volltextzugriff (PDF)

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy : pharmacological data from the Viradapt Study

AIDS (London), 2000-07, Vol.14 (10), p.1333-1339

2000

Volltextzugriff (PDF)

Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-Experienced Subjects with HCV Genotype 1 and HIV-Co-Infection Final Results of the ANRS HC31 Softrih Study

Journal of hepatology, 2016, Vol.64 (2), p.S764-S764

2016

Volltextzugriff (PDF)

Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers

European journal of ophthalmology, 2008-01, Vol.18 (1), p.13-20

2008

Volltextzugriff (PDF)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection: Antiviral Res

Antiviral research, 2020-09, Vol.181

2020

Volltextzugriff (PDF)

The suppression of immune activation during enfuvirtide‐based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin‐12 and IP‐10 during 48 weeks of longitudinal follow‐up

HIV medicine, 2011-02, Vol.12 (2), p.65-77

2011

Volltextzugriff (PDF)

Recurrence and Occurrence of Kaposi’s Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia

Clinical infectious diseases, 2020-05, Vol.70 (11), p.2435-2438

2020

Volltextzugriff (PDF)

Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment

AIDS (London), 2012-01, Vol.26 (3), p.303-314

2012

Volltextzugriff (PDF)

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

AIDS (London), 2009-04, Vol.23 (7), p.817-824

2009

Volltextzugriff (PDF)

Substitution d'un inhibiteur de protéase par un inhibiteur non nucléosidique de la transcriptase inverse 18 mois de suivi

La Presse médicale (1983), 2000-12, Vol.29 (37), p.2038-2039

GARRAFFO, R

2000

Volltextzugriff (PDF)

Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial

British journal of dermatology (1951), 2003-01, Vol.148 (1), p.142-146

2003

Volltextzugriff (PDF)

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance

Journal of clinical virology, 2005-05, Vol.33 (1), p.75-78

2005

Volltextzugriff (PDF)

PharmAdapt: A randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results

AIDS (London), 2002-11, Vol.16 (17), p.2311-2315

2002

Volltextzugriff (PDF)

Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy

AIDS (London), 2015-08, Vol.29 (13), p.1665-1671

2015

Volltextzugriff (PDF)

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients

PloS one, 2015-10, Vol.10 (10), p.e0141164-e0141164

2015

Volltextzugriff (PDF)

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

Journal of antimicrobial chemotherapy, 2017-01, Vol.72 (1), p.240-245

2017

Volltextzugriff (PDF)

Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

Journal of antimicrobial chemotherapy, 2015-06, Vol.70 (6), p.1816-1824

2015

Volltextzugriff (PDF)

Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients

Diabetes & metabolism, 2019-12, Vol.45 (6), p.573-581

2019

Volltextzugriff (PDF)

Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era — Role of chronic renal disease

The Journal of nutrition, health & aging, 2016-04, Vol.20 (4), p.408-414

2016

Volltextzugriff (PDF)

Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

AIDS research and human retroviruses, 2020-05, Vol.36 (5), p.399

2020

Volltextzugriff (PDF)

Ribavirin and abacavir drug interaction in HIV―HCV coinfected patients: fact or fiction?

AIDS (London), 2012-11, Vol.26 (17), p.2193-2199

2012

Volltextzugriff (PDF)

Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults

AIDS (London), 2009-05, Vol.23 (8), p.1021-1024

2009

Volltextzugriff (PDF)

Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach

Clinical microbiology and infection, 2003-05, Vol.9 (5), p.339-348

2003

Volltextzugriff (PDF)

Pharmacologie des inhibiteurs non nucléosidiques de la transcriptase inverse du VIH: Les inhibiteurs non nucléosidiques de la transcriptase inverse

Virologie (Montrouge, France), 2008, Vol.12 (OCT)

GARRAFFO, R

2008

Volltextzugriff (PDF)

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data

Journal of antimicrobial chemotherapy, 2009-09, Vol.64 (3), p.599-606

2009

Volltextzugriff (PDF)

1 – 25 von 216

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(166)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(118)
Humans
(113)
Life Sciences & Biomedicine
(102)
Male
(74)
Female
(71)
Adult
(67)
Biological And Medical Sciences
(65)
Infectious Diseases
(57)
Medical Sciences
(53)
Middle Aged
(51)
Hiv Infections - Drug Therapy
(43)
Pharmacology. Drug Treatments
(42)
Pharmacology & Pharmacy
(37)
Animals
(31)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(30)
Human Immunodeficiency Virus
(29)
Hiv
(26)
Life Sciences
(24)
Immunology
(21)
Aids/hiv
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of Tipranavir/Ritonavir Combination on the Pharmacokinetics of Tadalafil in Healthy Volunteers

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy : pharmacological data from the Viradapt Study

Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-Experienced Subjects with HCV Genotype 1 and HIV-Co-Infection Final Results of the ANRS HC31 Softrih Study

Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection: Antiviral Res

The suppression of immune activation during enfuvirtide‐based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin‐12 and IP‐10 during 48 weeks of longitudinal follow‐up

Recurrence and Occurrence of Kaposi’s Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia

Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

Substitution d'un inhibiteur de protéase par un inhibiteur non nucléosidique de la transcriptase inverse 18 mois de suivi

Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance

PharmAdapt: A randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results

Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients

Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era — Role of chronic renal disease

Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

Ribavirin and abacavir drug interaction in HIV―HCV coinfected patients: fact or fiction?

Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults

Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach

Pharmacologie des inhibiteurs non nucléosidiques de la transcriptase inverse du VIH: Les inhibiteurs non nucléosidiques de la transcriptase inverse

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data

Suchergebnisse filtern